Please select the option that best describes you:
Do you use denosumab for castration-sensitive prostate cancer with osseous metastases?
Only the mCRPC population was included in the Fizazi et al. study, but the FDA approval is for prevention of skeletal related events from any solid tumor with metastases to bone.
Answer from: Medical Oncologist at Academic Institution
At a minimum, the use of denosumab every 6 months in met HSPC should be considered. The frequency of denosumab should be decreased from the monthly use as patients with prostate cancer are living longer. The incidence of osteonecrosis appears to be higher with years of therapy and the risk of toxici...
Answer from: Medical Oncologist at Academic Institution
Skeletal related events in patients with metastatic bone disease are mediated by osteoclasts induced bone destruction. Receptor activator of nuclear factor kappa-B ligand (RANKL), are expressed by cells of osteoblasts lineage and activate RANK receptors on osteocalsts and its pre...
Comments
Medical Oncologist at Vita Medical Associates, P.C.
MMR
MMR
Answer from: Medical Oncologist at Community Practice
Great review! I am going to cut this out for my fellows. Anecdotally, I have seen several cases of profound hypocalcemia due to denosumab and invariably, it was in patients with hormone sensitive disease, which somewhat makes sense.
Agree with Dr. @Andrew J. Armstrong. Just to add -...
We have the occasional patient with mHSPC who pres...